Compare IPST & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | BGLC |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.4M |
| IPO Year | 2024 | 2019 |
| Metric | IPST | BGLC |
|---|---|---|
| Price | $2.00 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 932.7K | 4.9K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,402,488.00 | $7,424,911.00 |
| Revenue This Year | $66.82 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $0.26 | $0.81 |
| 52 Week High | $283.20 | $4.97 |
| Indicator | IPST | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 37.10 |
| Support Level | $1.54 | N/A |
| Resistance Level | $2.80 | $1.39 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 3.70 | 23.50 |
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.